Marksans Pharma Ltd

About

Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products.

Our key focus areas lie in the OTC & prescription drugs that have wide-ranging applications across fields like Oncology, Gastroenterology, Antidiabetic, Antibiotics, Cardiovascular, Pain Management, Gynaecology, among others. [1]

Key Points

Revenue Mix [1]
Around 30% comes from Pain Management, 18% comes from Anti-Diabetic, 15% comes from Cardiovascular System(CVS), 13% comes from Cough & Cold, and the rest comes from Gastrointestinal, Central Nervous System(CNS), etc.

See full details
  • Market Cap 2,826 Cr.
  • Current Price 69.0
  • High / Low 97.6 / 48.0
  • Stock P/E 11.2
  • Book Value 21.7
  • Dividend Yield 0.36 %
  • ROCE 38.9 %
  • ROE 31.2 %
  • Face Value 1.00

Pros

  • Company is almost debt free.
  • Company has delivered good profit growth of 24.76% CAGR over last 5 years

Cons

  • The company has delivered a poor sales growth of 9.03% over past five years.
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2018 Dec 2018 Mar 2019 Jun 2019 Sep 2019 Dec 2019 Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
269 248 247 245 256 288 335 331 356 358 330 349
232 212 232 213 223 240 266 261 273 267 235 272
Operating Profit 37 36 16 32 34 47 69 70 83 91 95 77
OPM % 14% 15% 6% 13% 13% 16% 21% 21% 23% 25% 29% 22%
Other Income -1 0 10 2 8 0 0 0 4 -3 6 6
Interest 3 2 2 2 3 2 2 2 2 2 3 1
Depreciation 6 5 6 5 5 7 10 7 19 9 1 7
Profit before tax 28 30 17 28 34 38 58 61 66 78 97 75
Tax % 26% 15% 41% 19% 23% 23% 26% 20% 23% 24% 18% 16%
Net Profit 21 25 10 22 26 30 43 49 51 59 80 63
EPS in Rs 0.50 0.61 0.24 0.55 0.63 0.72 1.04 1.21 1.24 1.44 1.94 1.53

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2010 Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 TTM
359 305 356 438 630 797 893 767 913 1,000 1,134 1,376 1,394
336 378 455 369 512 612 757 722 834 868 942 1,037 1,047
Operating Profit 24 -73 -100 69 118 185 136 45 78 132 192 340 347
OPM % 7% -24% -28% 16% 19% 23% 15% 6% 9% 13% 17% 25% 25%
Other Income 2 -78 2 4 4 3 9 7 8 5 0 7 12
Interest 19 44 54 15 19 16 10 7 10 10 9 8 7
Depreciation 15 20 24 16 16 16 28 30 27 23 27 36 36
Profit before tax -9 -215 -175 44 86 156 107 15 50 104 157 302 316
Tax % -4% -3% -1% -12% 15% 28% 23% 24% 28% 23% 23% 21%
Net Profit -10 -223 -179 46 72 109 79 9 33 76 121 239 252
EPS in Rs 1.19 1.87 2.67 1.92 0.22 0.80 1.87 2.95 5.83 6.15
Dividend Payout % 0% 0% -0% 10% 5% 4% 21% 23% 6% 3% 3% 4%
Compounded Sales Growth
10 Years:16%
5 Years:9%
3 Years:15%
TTM:15%
Compounded Profit Growth
10 Years:12%
5 Years:25%
3 Years:93%
TTM:71%
Stock Price CAGR
10 Years:41%
5 Years:5%
3 Years:33%
1 Year:45%
Return on Equity
10 Years:%
5 Years:17%
3 Years:23%
Last Year:31%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2010 Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
50 50 50 52 52 53 53 41 41 41 41 41
Reserves 111 -115 -220 34 90 326 401 392 430 502 595 846
Borrowings 424 135 179 163 160 89 88 110 118 100 30 34
86 436 389 165 202 220 192 209 142 160 236 307
Total Liabilities 658 492 385 401 490 676 722 752 731 802 902 1,227
392 279 165 156 146 166 270 267 279 270 303 309
CWIP 0 0 0 0 0 0 0 0 0 0 0 12
Investments 10 0 0 0 0 0 0 0 0 0 0 0
256 213 220 245 344 510 452 484 451 533 599 906
Total Assets 658 492 385 401 490 676 722 752 731 802 902 1,227

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2010 Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
17 -65 -62 39 65 155 31 14 50 27 233 179
-35 25 -3 -5 -4 -33 -123 -21 -39 -13 -60 -45
32 36 57 -40 -29 17 -58 -3 3 -21 -114 -15
Net Cash Flow 13 -5 -9 -7 31 138 -150 -10 15 -7 60 119

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2010 Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Debtor Days 96 118 116 109 98 84 89 118 71 64 78 72
Inventory Days 149 210 126 112 102 107 120 151 152 215 155 248
Days Payable 85 172 100 81 83 88 85 129 54 78 71 103
Cash Conversion Cycle 160 156 141 141 118 103 124 140 169 202 163 217
Working Capital Days 163 -270 -167 71 68 58 95 130 118 133 94 110
ROCE % 2% -28% -306% 45% 38% 45% 23% 4% 11% 19% 25% 39%

Shareholding Pattern

Numbers in percentages

Sep 2018 Dec 2018 Mar 2019 Jun 2019 Sep 2019 Dec 2019 Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
48.25 48.25 48.25 48.25 48.25 48.25 48.25 48.25 48.25 48.25 48.25 48.25
4.09 3.59 3.45 3.18 2.46 2.44 2.54 3.28 4.69 5.05 4.34 3.14
0.47 0.50 0.62 0.51 0.66 0.64 0.89 0.67 0.30 0.30 0.34 0.56
47.19 47.66 47.68 48.06 48.64 48.67 48.32 47.80 46.76 46.40 47.07 48.05

Documents